An Open-Label, Parallel-Group, Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Delayed-Release Dimethyl Fumarate in Chinese, Japanese, and Caucasian Adult Healthy Volunteers.

被引：0
|
作者：
Tibung, J. T. [1 ]
Nestorov, I. [2 ]
McNeill, M. [3 ]
Li, J. [2 ]
Zhu, B. [2 ]
机构：
[1] Biogen Ltd, Tokyo, Japan
[2] Biogen Inc, 14 Cambridge Ctr, Cambridge, MA 02142 USA
[3] Biogen UK Ltd, Maidenhead, Berks, England
来源：
MULTIPLE SCLEROSIS JOURNAL | 2016年 / 22卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P-47
引用
收藏
页码：422 / 422
页数：1
相关论文
共 50 条
  • [31] OPEN-LABEL, DOSE-ESCALATION, PHASE 1 STUDY OF SAFETY AND PHARMACOKINETICS OF DICHLOR-PHENAMIDE IN HEALTHY VOLUNTEERS
    Cohen, F.
    MUSCLE & NERVE, 2017, 56 : S10 - S10
  • [32] A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment
    Bola Tayo
    Lesley Taylor
    Farhad Sahebkar
    Gilmour Morrison
    Clinical Pharmacokinetics, 2020, 59 : 747 - 755
  • [33] A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment
    Tayo, Bola
    Taylor, Lesley
    Sahebkar, Farhad
    Morrison, Gilmour
    CLINICAL PHARMACOKINETICS, 2020, 59 (06) : 747 - 755
  • [34] Pharmacokinetics, pharmacodynamics, and tolerability of BCD-017, a novel pegylated filgrastim: Results of open-label controlled phase I study with dose escalation in healthy volunteers.
    Nikitin, Kirill D.
    Fitilev, Sergei B.
    Chernovskaya, Tatiana V.
    Rudenko, Elena G.
    Vozzhaev, Alexander V.
    Titarova, Yulia Y.
    Yakushev, Vadim A.
    Ivanov, Roman A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [35] Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with severe renal impairment: A single-dose, open-label, parallel-group study
    Gardin, Anne
    Dodman, Angela
    Kalluri, Sampath
    Neelakantham, Srikanth
    Tan, Xuemei
    Legangneux, Eric
    Shakeri-Nejad, Kasra
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2017, 55 (01) : 54 - 65
  • [36] Pharmacokinetics, Safety, and Tolerability of Oxfendazole in Healthy Adults in an Open-Label Phase 1 Multiple Ascending Dose and Food Effect Study
    Bach, Thanh
    Galbiati, Shirley
    Kennedy, Jessie K.
    Deye, Gregory
    Nomicos, Effie Y. H.
    Codd, Ellen E.
    Garcia, Hector H.
    Horton, John
    Gilman, Robert H.
    Gonzalez, Armando E.
    Winokur, Patricia
    An, Guohua
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (11)
  • [37] Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A
    Taylor, Claribel P.
    Tummala, Sanjeev
    Molrine, Deborah
    Davidson, Lisa
    Farrell, Richard J.
    Lembo, Anthony
    Hibberd, Patricia L.
    Lowy, Israel
    Kelly, Ciaran P.
    VACCINE, 2008, 26 (27-28) : 3404 - 3409
  • [38] An open-label, parallel, multiple-dose study comparing the pharmacokinetics and gastric acid suppression of rabeprazole extended-release with esomeprazole 40 mg and rabeprazole delayed-release 20 mg in healthy volunteers
    Morelli, G.
    Chen, H.
    Rossiter, G.
    Rege, B.
    Lu, Y.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2011, 33 (07) : 845 - 854
  • [39] Rimegepant 75 mg Exposure, Safety, and Tolerability are Similar in Elderly and Nonelderly Adults: a Phase 1, Open-Label, Parallel-Group, Single-Dose Study
    Ivans, Andrea
    Stringfellow, Joseph
    Coric, Vlad
    Croop, Robert
    NEUROLOGY, 2020, 94 (15)
  • [40] Rimegepant 75 mg Exposure, Safety, and Tolerability are Similar in Elderly and Nonelderly Adults: a Phase 1, Open-Label, Parallel-Group, Single-Dose Study
    Croop, Robert
    Stringfellow, Joseph
    Ivans, Andrea
    Coric, Vladimir
    CEPHALALGIA, 2019, 39 : 30 - 30
12345